{"id":"W4417172069","doi":"10.1097/ju.0000000000004890","title":"Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial","year":2025,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"CancerCare Manitoba; University of British Columbia","funders":"","keywords":"Enzalutamide; Recurrent prostate cancer; Prostate cancer; Clinical endpoint; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002514871,0.001010333,0.001495806,0.0002947207,0.0002158393,0.0007237704,0.0004854815,0.0007371461,0.003318013],"category_scores_gemma":[0.001240268,0.0002002153,0.00160416,0.000311731,0.0003836003,0.0004909578,0.0003056201,0.00198421,0.0004606906],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005206614,"about_ca_system_score_gemma":0.0005107881,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004403896,"about_ca_topic_score_gemma":0.00230007,"domain_scores_codex":[0.9988698,0.0007824431,0.00006427347,0.0001133084,0.00009457595,0.0000755727],"domain_scores_gemma":[0.9992519,0.0002051728,0.0002286771,0.00004495303,0.00006667626,0.0002024783],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9014766,0.00493787,0.00922008,0.003133927,0.009185641,0.0001426863,0.000055617,0.001775405,0.007896572,0.0002462698,0.004385544,0.05754388],"study_design_scores_gemma":[0.7000012,0.2215937,0.05277898,0.0004774407,0.009599513,0.0005822663,0.00007889051,0.001921986,0.004402726,0.0005350825,0.007954179,0.00007396475],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9643472,0.02487448,0.0007140468,0.00116562,0.0003095269,0.0008449595,0.002709766,0.0001005958,0.004933809],"genre_scores_gemma":[0.9875936,0.004071875,0.000765241,0.001100143,0.0003311687,0.0008816206,0.003317301,0.0000184886,0.001920579],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003318013,"threshold_uncertainty_score":0.01330006,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0132571991054753,"score_gpt":0.2990099940819483,"score_spread":0.285752794976473,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}